The global Drug of Abuse Testing (DOA) market was valued at $2,866.7 miilion in 2014. The DoA market is expected to grow at a CAGR of 5.3% during 2015 to 2020, to reach $3,895.5 million by 2020. Two main drivers leading to growth of drug of abuse market are significant increase in the use of illicit drugs and rising need for drug testing at organizational level. North America, the largest market by size in the drugs of abuse testing, is expected to grow at a CAGR of 5.8% during 2015 to 2020. With North America being the largest region for drug of abuse testing, Europe comes second. The Asian market is expected to show high growth rate in the drug testing equipment, mainly due to rise in alcohol consumption and strict government rules and regulations on testing alcohol consumption in the region.
Several countries in America and Europe are using drug screening tests at various organizational levels, such as on the spot drug/alcohol screening, pre-employment screening, post incident drug/alcohol screening and abstinence monitoring. Government regulations in the countries are also supporting the growth of DOA Testing Market, mainly through practice of drug testing at workplace. The number of strategic collaborations, mergers and acquisitions in the drug of abuse testing market is increasing globally for enhancing the quality, performance and portfolio of products.
A major factor leading to the rise of DOA has been the increased use of illicit drugs. The use of illicit drugs is rising every year globally and has become a big concern for countries including the U.S., the U.K. Japan, Germany, India and China. A major challenge faced by the drug of abuse testing market is the failure to spot designer drugs such as LSD, Rohypnol and ecstasy.
Drug of abuse testing market can be segmented into two categories based on type of tests; laboratory based drugs of abuse tests and onsite drugs of abuse tests. Laboratory based tests requires skilled and trained personnel for providing detailed analysis whereas, onsite drugs of abuse testing provide immediate results.
The North American laboratory as well as onsite testing market has increased with more than 5.0% CAGR over the period 2011 to 2014, with onsite market standing at double the size of the laboratory testing market. In Europe, onsite testing had a market size of $346.1 million in 2014 and it is expected to grow at a faster rate than laboratory testing market during the period 2015 to 2020.
The most common samples used for onsite testing are urine, saliva and hair. Whilst for many years, urine testing has been considered the standard in onsite testing, saliva testing is gaining significance. These tests give immediate results and are highly preferred at workplace and educational institutions. Nowadays, commercially available onsite drugs of abuse screening test kits are usually designed for urine and saliva specimens. In terms of sample, urine held major share in the global DOA market, and it also witnessed highest CAGR of 5.1% during the period 2011 to 2014.
The major companies operating in the drug of abuse testing market include Roche Holding Limited, Quest Diagnostics, Laboratory Corporation of America Holdings, Alere, Inc., Abbott Laboratories, Randox laboratories, Psychemedics Corporation, Bio-Rad Laboratories, Sonic Healthcare and Thermo Fisher Scientific.
News Courtesy: P&S Market Research
Tagged: drug of abuse testing market, healthcare industry, medical devices